EGFR and lung cancer: The efficacy of osimertinib has previously been demonstrated in two clinical trials in patients with EGFR-positive lung cancer and good PS, where the T790M variant was confirmed after treatment—the phase III AURA3 study that compared osimertinib with platinum-doublet chemotherapy (median age: 62 years) [10] and a pooled analysis of the phase II AURA and AURA2 studies (median age: 62 years) [14, 15].